Evotec SE Total Liabilities
Evotec SE total liabilities. Based on the latest financial reports, Evotec SE (EVT) has total liabilities worth €908.40 Million EUR (≈ $1.06 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Evotec SE (EVT) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Evotec SE (2003–2025)
Total liabilities of Evotec SE from 2003 to 2025. This chart illustrates how Evotec SE's total liabilities have evolved over time, based on quarterly financial data. Explore EVT long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Evotec SE Competitors by Total Liabilities
The table below lists competitors of Evotec SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Xinneng Photovoltaic Technology Co Ltd
SHG:603105
|
China | CN¥2.37 Billion |
|
Ipek Dogal Enerji Kaynaklari Arastirma ve Uretim AS
IS:IPEKE
|
Turkey | TL4.00 Billion |
|
Voyager Acquisition Corp
NASDAQ:VACH
|
USA | $286.73 Million |
|
Hunan Yussen Energy Technology
SHE:002986
|
China | CN¥5.71 Billion |
|
China Hi-Tech Group Co Ltd
SHG:600730
|
China | CN¥228.71 Million |
|
Ennis Inc
NYSE:EBF
|
USA | $49.46 Million |
|
PIERER Mobility AG
VI:PKTM
|
Austria | €1.44 Billion |
|
Asia Aviation Public Company Limited
BK:AAV-R
|
Thailand | ฿65.62 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Evotec SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Evotec SE.
Liquidity & Leverage Metrics
Evotec SE Total Liabilities Ratios Explained
Evotec SE total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evotec SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evotec SE (2003–2025)
The table below shows the annual total liabilities of Evotec SE from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €965.05 Million ≈ $1.13 Billion |
+0.53% |
| 2024-12-31 | €959.98 Million ≈ $1.12 Billion |
-15.24% |
| 2023-12-31 | €1.13 Billion ≈ $1.32 Billion |
+5.84% |
| 2022-12-31 | €1.07 Billion ≈ $1.25 Billion |
+24.79% |
| 2021-12-31 | €857.48 Million ≈ $1.00 Billion |
+16.21% |
| 2020-12-31 | €737.88 Million ≈ $862.66 Million |
+4.83% |
| 2019-12-31 | €703.88 Million ≈ $822.91 Million |
+102.85% |
| 2018-12-31 | €347.00 Million ≈ $405.68 Million |
+3.42% |
| 2017-12-31 | €335.52 Million ≈ $392.26 Million |
+144.14% |
| 2016-12-31 | €137.43 Million ≈ $160.67 Million |
+35.47% |
| 2015-12-31 | €101.44 Million ≈ $118.60 Million |
+53.20% |
| 2014-12-31 | €66.22 Million ≈ $77.41 Million |
-3.21% |
| 2013-12-31 | €68.41 Million ≈ $79.98 Million |
-6.13% |
| 2012-12-31 | €72.88 Million ≈ $85.20 Million |
+2.69% |
| 2011-12-31 | €70.97 Million ≈ $82.97 Million |
+19.83% |
| 2010-12-31 | €59.22 Million ≈ $69.24 Million |
+68.67% |
| 2009-12-31 | €35.11 Million ≈ $41.05 Million |
+6.27% |
| 2008-12-31 | €33.04 Million ≈ $38.63 Million |
-11.48% |
| 2007-12-31 | €37.33 Million ≈ $43.64 Million |
-45.39% |
| 2006-12-31 | €68.35 Million ≈ $79.91 Million |
+82.55% |
| 2005-12-31 | €37.44 Million ≈ $43.77 Million |
+307.75% |
| 2004-12-31 | €9.18 Million ≈ $10.74 Million |
+61.18% |
| 2003-12-31 | €5.70 Million ≈ $6.66 Million |
-- |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more